Voya Investment Management LLC Buys 24,790 Shares of Myriad Genetics, Inc. $MYGN

Voya Investment Management LLC lifted its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 51.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 72,572 shares of the company’s stock after buying an additional 24,790 shares during the quarter. Voya Investment Management LLC owned about 0.08% of Myriad Genetics worth $644,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. ProShare Advisors LLC grew its stake in Myriad Genetics by 12.2% in the fourth quarter. ProShare Advisors LLC now owns 26,982 shares of the company’s stock valued at $370,000 after acquiring an additional 2,933 shares during the period. Squarepoint Ops LLC grew its holdings in Myriad Genetics by 27.0% during the fourth quarter. Squarepoint Ops LLC now owns 138,869 shares of the company’s stock valued at $1,904,000 after purchasing an additional 29,524 shares during the period. Voloridge Investment Management LLC bought a new position in Myriad Genetics during the fourth quarter worth about $1,635,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Myriad Genetics by 43.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 285,229 shares of the company’s stock worth $3,910,000 after acquiring an additional 86,973 shares during the period. Finally, GAMMA Investing LLC increased its holdings in Myriad Genetics by 520.8% during the 1st quarter. GAMMA Investing LLC now owns 4,470 shares of the company’s stock worth $40,000 after acquiring an additional 3,750 shares during the period. 99.02% of the stock is currently owned by institutional investors and hedge funds.

Myriad Genetics Stock Up 0.5%

NASDAQ:MYGN opened at $7.76 on Friday. Myriad Genetics, Inc. has a twelve month low of $3.76 and a twelve month high of $27.55. The stock has a market cap of $721.99 million, a P/E ratio of -1.81 and a beta of 1.93. The business’s 50-day moving average price is $6.00 and its two-hundred day moving average price is $6.31.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.